CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy

Gene Therapy

Volumn 18, Issue 3, 2011, Pages 313-317

  Yaiw, K C ^a   Miest, T S ^a   Frenzke, M ^a   Timm, M ^a   Johnston, P B ^a   Cattaneo, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD 20; lymphoma; oncolytic virotherapy

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; CELL SPECIFICITY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MANTLE CELL LYMPHOMA; MEASLES VIRUS; NONHODGKIN LYMPHOMA; ONCOLYTIC VIROTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA;

ANTIGENS, CD20; FLOW CYTOMETRY; GENE TARGETING; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, B-CELL, MARGINAL ZONE; MEASLES VIRUS; ONCOLYTIC VIROTHERAPY;

MEASLES VIRUS;

EID: 79952486788     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.150     Document Type: Article

References (20)

1. Cancer Facts & Figures 2009. Amer Cancer Soc 2009: 1-72.
2. Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park, NY) 2009; 23: 683-690.
3. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-882.
4. Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009; 8: 676-682.
5. Hu JCC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulo-cyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747. (Pubitemid 44876843)
6. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14: 7127-7137.
7. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330: 213-241.
8. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893-897. (Pubitemid 30664265)
9. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2: 105-106.
10. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dötsch C et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 1: 5773-5784.
11. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75: 2087-2096. (Pubitemid 32147548)
12. Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62-72. (Pubitemid 36305359)
13. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007; 67: 10939-10947. (Pubitemid 350145923)
14. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993; 67: 6025-6032. (Pubitemid 23277513)
15. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 2004; 78: 302-313. (Pubitemid 37549743)
16. Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66-73. (Pubitemid 29523413)
17. Ungerechts G, Frenzke ME, Yaiw KC, Miest TS, Johnston PB, Cattaneo R. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther 2010, but doi:10.1038/gt.2010.103.
18. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540. (Pubitemid 351850977)
19. Dingli D, Peng K-W, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646. (Pubitemid 38268954)
20. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-531.